<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87471">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02064751</url>
  </required_header>
  <id_info>
    <org_study_id>CRD_704</org_study_id>
    <nct_id>NCT02064751</nct_id>
  </id_info>
  <brief_title>MultiPoint Pacing Programming Guided by Noninvasive Hemodynamics</brief_title>
  <official_title>Noninvasive Hemodynamics for MultiPoint(TM) Pacing Programming in Cardiac Resynchronization Therapy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate noninvasive hemodynamics with MultiPoint™ Pacing
      (MPP) and biventricular (BiV) pacing under various vector combinations and paced delays in
      patients receiving cardiac resynchronization therapy (CRT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Systolic blood pressure changes in hemodynamics during BiV pacing and MPP</measure>
    <time_frame>up to 6-months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>echocardiographic changes to MPP programming guided by noninvasive hemodynamic measurements</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>End systolic volume will be assessed at 6-month follow-up visit and compared to that of baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>MultiPoint Pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRT with MultiPoint Pacing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT with MultiPoint Pacing</intervention_name>
    <arm_group_label>MultiPoint Pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemodynamic measurements for CRT device programming</intervention_name>
    <arm_group_label>MultiPoint Pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be scheduled to undergo de novo implant of a St. Jude Medical CRT-D system

          -  Be in NYHA II or III functional class with approved standard indication by ESC/EHRA
             Guidelines

          -  Have the ability to provide informed consent for study participation and be willing
             and able to comply with the Clinical Investigation Plan (CIP) described evaluations
             and follow-up schedule

        Exclusion Criteria:

          -  Have persistent or permanent atrial fibrillation

          -  Have a recent myocardial infarction within 40 days prior to enrollment

          -  Have undergone cardiac surgery or coronary revascularization procedure within 3
             months prior to enrollment or be scheduled for such procedures in the following 12
             months

          -  Have had a recent Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA)
             within 3 months prior to enrollment

          -  Have had intravenous inotropic support in the last 30 days

          -  Be scheduled or considered for heart transplantation over the next 12 months

          -  Be less than 18 years of age

          -  Be pregnant or plan to become pregnant over the next 12 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Leclercq, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Rennes, Rennes, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fujian Qu, DSc</last_name>
    <phone>408-522-6795</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Lercher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe Leclercq, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niguarda Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maurizio Lunati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maurizio Landolina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>February 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
